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Background: Anticoagulation therapy with heparin induces antibodies that recognize multimolecular complexes
of platelet factor 4 bound to heparin (anti–platelet factor 4/heparin antibodies). Considering that cardiac surgery
induces an intense platelet activation and proinflammatory response, we examined the relationship between for-
mation of anti–platelet factor 4/heparin antibodies and plasma levels of platelet factor 4 and interleukin 6. We also
examined the relationship between anti–platelet factor 4/heparin seroconversion and the histocompatibility leu-
kocyte antigen system.
Methods: In 71 patients undergoing cardiac surgery, anti–platelet factor 4/heparin antibody levels were evaluated
by means of enzyme-linked immunosorbent assay preoperatively and 14 days postoperatively. Platelet serotonin
release assays were performed to assess the platelet-activating potential of the antibodies. Plasma levels of platelet
factor 4 and interleukin 6 were assayed at prespecified time points. Histocompatibility leukocyte antigen status
was assessed preoperatively in all patients and was compared with that of 6156 healthy subjects.
Results: Thirty-seven (52%) patients had anti–platelet factor 4/heparin antibodies with an OD value of 0.45 or
greater in 1 or more of the assays. Applying strict seroconversion criteria (>2-fold increase in Optical Density),
only 16 (22.5%) patients had evidence of anti–platelet factor 4/heparin antibody seroconversion after the oper-
ation. Neither the presence of anti–platelet factor 4/heparin antibodies nor seroconversion influenced postopera-
tive outcomes. The CW4 allele was significantly more frequent among seroconverted patients (46.9% vs 19.1%,
P ¼ .002). Platelet factor 4 levels did not influence seroconversion. Patients with anti–platelet factor 4/heparin
levels of 0.45 OD units or greater 14 days after the operation had significantly higher interleukin 6 levels mea-
sured 1 hour after protamine administration.
Discussion: Patients with a greater amount of perioperative inflammation could be more likely to have anti–plate-
let factor 4/heparin antibodies 1 to 2 weeks later. We provide additional evidence that the histocompatibility
leukocyte antigen CW4 confers genetic susceptibility in an acquired inflammatory disorder that includes the
anti–platelet factor 4/heparin immune response.Immune heparin-induced thrombocytopenia (HIT) is an im-
mune-mediated complication of anticoagulation therapy
with heparin. HIT is caused by platelet-activating antibodies
that recognize multimolecular complexes of platelet factor 4
(PF4), a member of the C-X-C subfamily of chemokines,
when PF4 is bound to heparin (anti-PF4/heparin [anti-PF4/
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lar complexes of heparin, PF4, and IgG form on platelet sur-
faces, producing ‘‘strong’’ platelet activation through
clustering of the platelet Fcg receptors, with an associated
decrease in the platelet count. HIT and its attendant throm-
botic complications affect only a relatively small proportion
of patients after cardiac surgery who form very high levels of
platelet-activating anti-PF4/H antibodies.2,3
The factors that influence the anti-PF4/H immune re-
sponse are poorly understood. One possible factor is the his-
tocompatibility leukocyte antigen (HLA) system, which
modulates the immune response through its influence both
in antigen recognition and cellular effector action. HLA mol-
ecules are glycoproteins expressed on the cell membranes of
many different cell types.4 Few and conflicting data exist
regarding whether the HLA system influences anti-PF4/H
seroconversion.5,6 Other nongenetic factors could also influ-
ence the anti-PF4/H immune response. Considering that
cardiac surgery induces intense platelet activation7 andrgery c December 2008
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ACT ¼ activated clotting time
anti-PF4/H ¼ anti–platelet factor 4/heparin
CPB ¼ cardiopulmonary bypass
ELISA ¼ enzyme-linked immunosorbent assay
HIT ¼ heparin-induced thrombocytopenia
HLA ¼ histocompatibility leukocyte antigen
IL-6 ¼ interleukin 6
LMWH ¼ low-molecular-weight heparin
OD ¼ optical density
PF4 ¼ platelet factor 4
SRA ¼ serotonin release assay
UFH ¼ unfractionated heparin
a proinflammatory response,8 it is possible that the magni-
tude of these events can also influence the risk of antibody
formation. Despite PF4 being released from activated plate-
lets and being a component within the antigen complex of
HIT, the relationship between perioperative plasma levels
of PF4 and formation of anti-PF4/H antibodies is unknown.
Moreover, the possible correlation between the periopera-
tive inflammatory response and anti-PF4/H antibody forma-
tion has not been explored previously. We hypothesized that
the anti-PF4/H immune response could reflect the interac-
tion of a patient’s genetic status (HLA antigens), as well
as PF4 concentrations (related to perioperative platelet acti-
vation and associated PF4 release), a costimulatory effect of
perioperative inflammation (as assessed based on interleu-
kin-6 [IL-6] plasma levels), or both. By investigating these
3 parameters in one study, we have the potential to determine
whether any one (or more) of these is of greater relevance in
determining the anti-PF4/heparin immune response.
MATERIALS AND METHODS
Seventy-one elective cardiac surgery patients undergoing either cardio-
pulmonary bypass (CPB; n ¼ 56) or off-pump cardiac surgery (n ¼ 15)
in our institution between January 2004 and June 2006 were enrolled in
this prospective observational study. Exclusion criteria consisted of 1 or
more of the following: urgent or emergency operation, requirement for
deep hypothermia during CPB, preoperative thrombocytopenia (<100 3
109/L), known preoperative coagulopathy, chronic inflammatory disease,
and preoperative corticosteroid treatment. The institutional ethics commit-
tee approved the protocol, and informed consent was obtained from all
patients entered into the study.
Operative Technique
The surgical approach was always a median sternotomy. Heparin was ad-
ministered (300 U/kg), and CPB was performed at moderate hypothermia
(34C) with noncoated open systems and membrane oxygenators (Dideco,
Sorin Group, Italy). Cardiac arrest was induced and maintained with cold
blood cardioplegia. Intraoperative heparin monitoring was performed by us-
ing standard activated clotting time (ACT; Hemochron 8). Additional hep-
arin boluses (5000 U) were administered if the ACT values were less thanThe Journal of Thoracic and Ca400 seconds. Protamine was administered to reverse heparin (1 mg of prot-
amine per milligram of total heparin given before and during CPB). For pa-
tients undergoing off-pump operations, anesthesia management was not
different from that used for patients undergoing CPB. Heparin was admin-
istered at the same dose (300 U/kg), and additional boluses were adminis-
tered only if ACT values decreased to less than 250 seconds. Tranexamic
acid was used in all patients undergoing valve surgery and in those patients
undergoing coronary artery bypass grafting in whom the risk of periopera-
tive bleeding was considered high.
Definitions
Systemic hypertension was defined as blood pressure exceeding 140/90
mm Hg, a history of high blood pressure, or need for medications. Those
having a history of diabetes regardless of the duration of disease or the
need for antidiabetic agents were considered diabetic. Hypercholesterol-
emia was defined as a fasting cholesterol level of greater than 200 mg/dL.
Smoking history was defined as any current or past form of tobacco use.
Chronic obstructive pulmonary disease was defined as a forced expiratory
volume in 1 second of less than 75% of predicted value or the need for phar-
macologic therapy for the treatment of chronic pulmonary compromise. On-
going refractory angina that required the use of intravenous nitrate therapy
for control was regarded as unstable angina. The Euroscore was calculated
by using the additive method.
Death within the same hospital admission, regardless of cause, was de-
fined as in-hospital mortality. Low cardiac output syndrome was defined
as the need for postoperative inotropic support for more than 12 hours or
an intra-aortic balloon pump for more than 30 minutes to maintain systolic
blood pressure greater than 90 mm Hg, mean blood pressure greater than 60
mm Hg, or cardiac index greater than 2.2 L$min1$m2, despite sufficient
volume substitution. Extubation criteria were hemodynamic stability, ab-
sence of surgical bleeding, fully rewarmed state, consciousness, and optimal
blood gases with a fraction of inspired oxygen of 0.3 or less. Acute cerebro-
vascular events were regarded as any postoperative transient ischemic acci-
dent, reversible ischemic neurologic deficit, or stroke.
Blood and blood products were transfused to patients showing hypovo-
lemia according with the following criteria. Packed red blood cells were
transfused if the hemoglobin value was less than 8 g/dL. Fresh frozen
plasma was infused if the prothrombin time (PT) value after protamine ad-
ministration was at least 1.5 times the baseline in presence of significant
bleeding, and platelet concentrates were transfused with platelet counts of
less than 50,000/mm3 in the presence of significant bleeding.
Serologic Analysis
Blood samples were collected preoperatively on the morning of the op-
eration (T0), 1 hour after the beginning of CPB (2 hours after the beginning
of the operation for off-pump cases, T1), 1 hour after protamine sulphate ad-
ministration (T2), and 14 days after the operation (T3). Blood samples were
centrifuged for 30 minutes at 3500 rpm and frozen at80C until assayed.
PF4 (a component of the PF4/heparin antigen complex) levels were mea-
sured at T0, T1, and T2. Blood was collected into previously cooled tubes
containing a solution of citric acid, theophylline, adenosine, and dipyrida-
mole. Plasma PF4 levels were assayed with an enzyme-linked immunosor-
bent assay (ELISA; Diagnostica Stago, Asniers, France).
Inflammatory system activation was evaluated by measuring IL-6 levels
at T0, T1, T2, and T3. Serum IL-6 levels were assayed with an ELISA (Im-
munotech, Beckman Coulter Company, Marseille, France).
All ELISAs were performed in duplicate, and the mean value was used
for analysis. Results were corrected for hemodilution according to the fol-
lowing formula:
½Corrected assayTx ¼ ½AssayTx3½HematocritT0
=½HematocritTx:rdiovascular Surgery c Volume 136, Number 6 1457
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Assessment of anti-PF4/H antibody levels was performed at T0 and T3.
All samples were tested with ELISAs for anti-PF4/H antibodies of IgG, IgA,
and IgM classes, as previously described.9 The positive antibody cutoff was
0.45 OD units. Any sample that produced an OD of less than 0.45 was con-
sidered negative. All samples that produced absorbance (quantitated as units
of optical density [OD]0.45) were repeated in the presence and absence of
high heparin doses (100 U/mL final). A patient sample set was considered as
indicating a positive seroconversion event for anti-PF4/H antibodies (by any
of the 3 immunoglobulin classes: IgG, IgA or IgM) if all of the following
criteria were met: (1) the follow-up T3 sample was positive (0.45 OD);
(2) the follow-up T3 sample had an OD value of at least double that of
the baseline T0 sample; and (3) the follow-up T3 sample was inhibited by
more than 50% by the addition of 100 U/mL heparin.
Platelet Serotonin Release Assay
We screened in the serotonin release assay (SRA) any patient sample that
produced an OD of 0.45 or greater for anti-PF4/H IgG antibodies by testing
the serum at 3 concentrations of heparin (ie, the 3-point SRA screen) known
to produce optimal platelet activation (0.1 and 0.3 U/mL for unfractionated
heparin [UFH] and 0.2 U/mL for low-molecular-weight heparin [LMWH]).
Any sample that did not produce 10% or greater release in this screening
phase was considered negative. Any sample that produced 10% or greater
release at any of the 3 concentrations tested underwent repeat testing in the
‘‘full-screen SRA,’’ in which testing was performed in all of the following
reaction conditions: final concentrations of 0, 0.1, 0.3, 100, and 0.1 plus Fc-
blocking monoclonal antibody (IV.3) and 0.1 plus 8 U/mL hirudin for UFH
and final concentration of 0.2 U/mL for LMWH. The mean release was re-
ported for those 4 reaction conditions in which reactivity was expected for
a positive serum: UFH final concentrations of 0.1, 0.3, and 0.1 plus 8 U/mL
hirudin and LMWH final concentration of 0.2 U/mL. The SRA result was
considered positive if all the following criteria were met: (1) the mean re-
lease of these 4 reactions was 20% or greater; (2) the release was less
than 10% with 100 U/mL UFH and 0.1 U/mL UFH in the presence of
the Fc-blocking monoclonal antibody; and (3) the sample seroconverted
from a negative baseline T0 sample. These criteria were chosen to ensure
a high specificity for detecting definite seroconversion of heparin-dependent
platelet-activating antibodies.
HLA Tissue Typing
Evaluations were performed preoperatively (T0). Patients were typed for
HLA class I (loci B and C) by using the serologic complement-dependent
cytotoxicity method.10 Allelic frequencies of seroconverted and nonsero-
converted patients were compared with those of the 6156 healthy subjects
residing in the same geographic region.
Statistical Analysis
All categorical variables were presented as absolute numbers and per-
centages and were compared with Fisher’s exact test. Continuous variables,
if normally distributed, were presented as means  standard deviations and
were compared by using the t test. Nonnormally distributed variables were
presented as medians (interquartile ranges) and were compared by using the
Mann–Whitney test in unpaired comparisons or the Wilcoxon signed-rank
test in paired comparisons.
To quantify the whole amount of IL-6, PF4, and platelet levels through
the study period, areas under the curve were calculated for each of these pa-
rameters by using the trapezoidal rule. Linear regressions were used to eval-
uate the influence of preoperative anti-PF4/H antibody levels on
postoperative IL-6 levels. In HLA association analysis, significant P values
were corrected according to the Bonferroni method. The peak IL-6 level af-
ter CPB was the end point used to calculate the sample size for this study. A
previous article on the release of inflammatory markers after CPB11 was
used to assess the average release of IL-6 after CPB. A 50% anti-PF4/H1458 The Journal of Thoracic and Cardiovascular Santibody–positive status (OD>0.45) 2 weeks after cardiac surgery was hy-
pothesized; thus 2 equal groups (anti-PF4/H antibody positive vs negative)
were assumed. On this basis, a sample size of 70 patients had a power of 0.8
(a ¼ .05) to identify a 1.65-fold increase in post-CPB IL-6 peak levels in
patients with a positive anti-PF4/H antibody status. Statistical analyses
were carried out with Statview for Windows version 5.0 (SAS Institute,
Inc, Cary, NC).
RESULTS
Patients underwent different types of operations, the ma-
jority being coronary artery bypass grafting procedures
(Table 1). HLA association analysis (Table 2) demonstrated
that the CW4 allele was significantly more frequent among
patients demonstrating anti-PF4/H antibody seroconversion
compared with nonseroconverted patients (46.9% vs
19.1%, P¼ .002), even after Bonferroni adjustment. In con-
trast, for the B50 (9.4% vs 0.9%, P ¼ .03), A2 (34.4% vs
19.1%, P ¼ .09), and B35 (31.3% vs 15.5%, P ¼ .07) al-
leles, differences in frequency between the seroconverted
and nonseroconverted patient groups were also seen, but
these did not maintain a significant P value after Bonferroni
adjustment. Allelic frequencies of the healthy population
were different from those of seroconverted patients for the
CW4, B35, and B50 alleles, although only the CW4 differ-
ence remained significant after the Bonferroni correction. In-
stead, allelic frequencies of nonseroconverted patients were
very similar to those of the healthy population, except for
Cw7 frequency. Because the 3 alleles, CW4, B35, and
B50, appeared the most relevant, they were also examined
within the univariate comparison of preoperative character-
istics (Table 1).
Serologic analysis for the presence of anti-PF4/H anti-
bodies showed that 37 (52%) patients had an OD value of
0.45 or greater in 1 or more of the assays. Applying the se-
roconversion criteria previously described, however, only
16 (22.5%) patients had evidence of anti-PF4/H antibody
seroconversion after the operation. Eleven patients had pos-
itive results for IgG antibodies (9/11 with positive results for
IgG only and 2/11 with positive results for IgG and IgA).
Four patients had positive results for IgA alone, and 1 patient
had positive results for IgM alone.
Preoperative patient characteristics, preoperative pharma-
cologic treatment, perioperative variables, and HLA status
were analyzed to identify predictors of anti-PF4/H antibody
seroconversion. By means of univariate analysis (Table 1),
the only factors associated with seroconversion were the
presence of the B50 allele on locus B (P¼ .03) and the pres-
ence of the CW4 allele on locus C (P¼ .02). Operation type,
CPB time, off-pump procedures, and length of the operation
did not influence anti-PF4/H antibody formation. Intraoper-
ative heparin doses and time of heparin exposure during the
operation were recorded, and these factors also did not influ-
ence seroconversion.
Three patients had positive SRA results (2 positive results
for IgG only and 1 positive result for IgG and IgA). They hadurgery c December 2008
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PTABLE 1. Preoperative and intraoperative variables
All patients No seroconversion Seroconversion P value
No. of patients 71 55 16
Preoperative characteristics
Male sex 53 (74.6%) 42 (76.4%) 11 (68.8%) .53
HLA-B35 23 (32.3%) 16 (29.1%) 7 (43.7%) .36
HLA-B50 4 (5.6%) 1 (1.8%) 3 (18.7%) .03
HLA-Cw4 25 (35.2%) 15 (27.2%) 10 (62.5%) .02
Age (y) 65.1  8.5 65.9  8.3 62.5  8.9 .16
BMI (kg/m2) 26.8  3.4 26.7  3.4 27.1  3.5 .68
Systemic hypertension 49 (69%) 37 (67.3%) 12 (75%) .76
Diabetes mellitus 29 (40.8%) 25 (45.5%) 4 (25%) .16
Hypercholesterolemia 43 (60.6%) 34 (61.8%) 9 (56.3%) .77
Smoke 42 (59.2%) 30 (54.5%) 12 (75%) .16
Previous AMI 41 (57.7%) 32 (58.2%) 9 (56.3%) .99
LVEF (%) 48.9  10 48.3  8.8 50.6  9.4 .38
TIA/stroke 9 (12.7%) 6 (10.9%) 3 (18.8%) .41
PVD 9 (12.7%) 6 (10.9%) 3 (18.8%) .41
Intraoperative data
Operation with CPB 56 (78.9%) 44 (80%) 12 (75%) .73
CABG 49 (69%) 39 (70.9%) 10 (62.5%) .54
Valve surgery 7 (9.9%) 5 (9.1%) 2 (12.5%) .65
CPB duration (min) 117.1  42.1 113.3  30.1 131.3  65.7 .19
Clamp duration (min) 66.9  26.1 67.4  27.1 65.4  23.5 .81
OPCAB 15 (21.1%) 11 (20%) 4 (25%) .73
Grafts per patient 3.1  0.9 3.1  0.8 3.1  1.02 .82
Skin-to-skin time (min) 5.3  1.2 5.2  1.2 5.5  1.2 .27
Heparin (UI) 22,218  4320 22,364  4094 21,718  5141 .6
Heparin time (min) 160  49 157  42 169  68 .41
Tranexamic acid 37 (52.1%) 27 (49.1%) 10 (62.5%) .4
Tranexamic acid (mg) 1.64  1.68 1.56  1.72 1.93  1.56 .43
Continuous variables were presented as means  standard deviations. BMI, Body mass index; AMI, acute myocardial infarction; LVEF, left ventricular ejection fraction; TIA, tran-
sient ischemic accident; PVD, peripheral vascular disease; CPB, cardiopulmonary bypass; CABG, coronary artery bypass grafting; OPCAB, off-pump coronary artery bypass graft.an uneventful clinical course without evidence of HIT with
or without thrombosis.
One study patient died (overall mortality, 1.8%). The
death occurred on postoperative day 7 as a result of low
cardiac output syndrome without thrombocytopenia and
without anti-PF4/H antibodies detectable by means of
ELISA at T0. One other patient, who underwent successful
mitral valve repair, experienced a platelet count decrease
of greater than 50% (compared with the preoperative
value), which began 7 days after the operation, and anti-
PF4/H antibody seroconversion (but without a positive
SRA result) was detected in this patient. No signs of
thrombosis were apparent; however, the clinical outcome
was complicated by respiratory insufficiency and pro-
longed intensive care unit length of stay, and the thrombo-
cytopenia was considered to be secondary to critical
illness.
Neither the presence of preoperative anti-PF4/H anti-
bodies nor that of postoperative seroconversion (by 2-fold
increase in OD levels) influenced postoperative outcome;
in particular, no episodes of arterial or venous thrombosis
occurred. The incidence of postoperative complications ac-The Journal of Thoracic and Ccording to anti-PF4/H antibody seroconversion is described
in Table 3.
PF4 plasma levels increased significantly (from nonde-
tectable levels at T0) after the operation (Figure 1). How-
ever, no differences in PF4 levels were observed between
patients with anti-PF4/H antibody seroconversion versus
those who did not exhibit seroconversion, even when com-
paring the areas under the curve.
IL-6 levels increased significantly (from nondetectable
levels at T0) after the operation; no differences were
observed between patients undergoing operations with or
without CPB. IL-6 levels were similar in patients who had
anti-PF4/H antibody seroconversion versus levels in those
who did not exhibit seroconversion. However, 33 patients
who had an OD value of 0.45 or greater for anti-PF4/H an-
tibody at the postoperative (T3) time point had higher IL-6
levels compared with 37 anti-PF4/H antibody–negative pa-
tients, a finding that was significant at T2 (P ¼ .002). Even
excluding those patients (n ¼ 14) who had an OD value of
0.45 or greater for anti-PF4/H antibody preoperatively (T0),
IL-6 levels were significantly higher compared with those
seen in patients with negative results (P ¼ .006, Figure 2).ardiovascular Surgery c Volume 136, Number 6 1459
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(T0 vs T2, P< .0001), and after 14 days, they were signifi-
cantly higher than preoperative levels (T0 vs T3, P<.0001).
No difference in platelet count levels was found between se-
roconverted and nonseroconverted patients, however.
DISCUSSION
We prospectively evaluated the incidence of seroconver-
sion to anti-PF4/H antibodies in patients undergoing cardiac
surgery. Several previous studies have shown a high fre-
quency of anti-PF4/H antibodies after cardiac operations
(between 22% and 61% of the patients).6,12-14 Indeed, in
our study approximately half of the patients (52%) had an
OD value of 0.45 or greater in one or more of the assays, al-
though somewhat less than half of these patients (22% over-
all) met our more stringent criteria for a seroconversion
response after the operation. Heparin, a polyanion, has
a high affinity for the cationic chemokine PF4, which is
TABLE 2. Association between locus B and locus C alleles and anti-PF4/H antibody seroconversion status and comparison with allelic frequencies
of 6156 healthy subjects
Alleles No seroconversion Seroconversion P value* Healthy population P valuey P valuez
B7 6 (5.45%) 4 (12.5%) .23 757 (6.15%) .99 .13
B8 7 (6.36%) 0 (0%) .34 397 (3.22%) .09 .62
B13 4 (3.64%) 2 (6.25%) .61 583 (4.74%) .82 .66
B18 10 (9.09%) 4 (12.5%) .51 1403 (11.4%) .54 .78
B27 3 (2.73%) 0 (0%) .99 170 (1.38%) .19 .99
B35 17 (15.45%) 10 (31.25%) .07 1792 (14.55%) .78 .02
B38 1 (0.91%) 1 (3.13%) .4 496 (4.03%) .98 .99
B39 6 (5.45%) 0 (0%) .33 247 (2.01%) .02 .99
B44 15 (13.64%) 2 (6.25%) .36 943 (7.66%) .03 .99
B45 2 (1.82%) 0 (0%) .99 70 (0.57%) .13 .99
B49 4 (3.64%) 0 (0%) .57 515 (4.18%) .99 .64
B50 1 (0.91%) 3 (9.38%) .03 304 (2.47%) .52 .04
B51 9 (8.18%) 1 (3.13%) .45 1046 (8.5%) .99 .51
B55 2 (1.82%) 1 (3.13%) .53 229 (1.86%) .99 .45
B58 2 (1.82%) 0 (0%) .99 138 (1.12%) .35 .99
B60 2 (1.82%) 0 (0%) .99 172 (1.4%) .66 .99
B62 2 (1.82%) 2 (6.25%) .21 260 (2.11%) .99 .14
Cw1 5 (4.55%) 0 (0%) .58 289 (2.35%) .19 .99
Cw2 5 (4.55%) 0 (0%) .58 611 (4.96%) .99 .4
Cw3 5 (4.55%) 3 (9.38%) .37 575 (4.67%) .99 .18
Cw4 21 (19.09%) 15 (46.88%) .002 1915 (15.55%) .29 <.0001
Cw5 6 (5.45%) 3 (9.38%) .42 422 (3.43%) .28 .09
Cw6 15 (13.64%) 6 (18.75%) .57 1619 (13.15%) .88 .3
Cw7 43 (39.09%) 5 (15.63%) .02 2894 (23.51%) <.0001 .4
Data are analyzed as alleles (number of subjects3 2). Uncorrected significant P value .05; Bonferroni-corrected significant p value (.05/24)¼ .002. Anti-PF4/H, Anti–platelet
factor 4/heparin. *Comparison between seroconverted versus nonseroconverted patients. yComparison between the healthy population and nonseroconverted patients.
zComparison between the healthy population and seroconverted patients.
TABLE 3. Clinical outcome according to anti-PF4/H antibody seroconversion status
All patients No seroconversion Seroconversion P value
Patients 71 55 16
In-hospital mortality 1 (1.4%) 1 (1.8%) 0 (0%) .99
Mechanical ventilation (h) 10.9  11.2 9.7  5.3 15.4  21.8 .08
ICU stay (h) 34  30.1 34.2  31.1 33.4  31.1 .93
IABP 1 (1.4%) 0 (0%) 1 (6.3%) .22
Blood loss (mL) 663.7  403.7 664.6  428.8 660.6  311.2 .97
Blood units 1.6  1.8 1.6  1.9 1.7  1.5 .73
FFP (U) 0.2  0.8 0.2  0.7 0.07  .2 .48
Platelets (U) 0.2  1 0.22  1.16 0 .46
Acute renal failure 6 (8.5%) 4 (7.3%) 2 (12.5%) .61
Atrial fibrillation 16 (22.5%) 13 (23.6%) 3 (18.8%) .99
Sternal wound infection 5 (7%) 3 (5.5%) 2 (12.5%) .31
Anti-PF4/H, Anti–platelet factor 4/heparin; ICU, intensive care unit; IABP, intra-aortic balloon pump; FFP, fresh frozen plasma.1460 The Journal of Thoracic and Cardiovascular Surgery c December 2008
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PFIGURE 1. Box plot of platelet factor 4 (PF4) levels according to seroconversion. Data are presented as medians (interquartile ranges). In the entire pop-
ulation, a significant increase in PF4 levels was observed between T0 and T1 (P< .0001). However, no differences were seen in PF4 levels between sero-
converted and nonseroconverted patients.found within platelet a-granules and on the endothelium.
Antibodies of IgG class reactive against the multimolecular
PF4/H complexes can cause platelet activation through the
platelet FcgIIa receptors.1,15
It is well established that cardiac surgery, either with or
without CPB, induces platelet activation with the release
of their granule content (PF4, b-thromboglobulin, adenine,
and guanosine nucleotides): CPB-induced platelet ‘‘stress,’’
heparin administration, and hypothermia are considered the
main triggers of platelet activation in this context.7 Consid-
ering that seroconversion after cardiac surgery occurs much
more frequently than other clinical settings with heparin ex-
posure,2 we sought to test the hypothesis that the intense
platelet activation induced by cardiac operations, with the re-
sulting release of PF4 from platelets facilitating formation of
the immunogenic PF4/heparin complexes, could be respon-
sible for anti-PF4/H antibody seroconversion. Recently,
Rauova and colleagues,16 in a murine experimental model,
demonstrated that the development and severity of thrombo-
cytopenia depends on the surface PF4 and total PF4 levels.
Although our data indicate that significant amounts of PF4
are released in association with cardiac surgery, we found
no difference in perioperative plasma PF4 levels between
the patients who showed anti-PF4/H antibody seroconver-
sion and those who did not. We also found no difference
in anti-PF4/H antibody seroconversion frequencies between
patients undergoing operations with or without CPB,
a finding that confirms the observations of Francis and
associates.17
In our study the presence of anti-PF4/H antibodies did not
influence clinical outcome. It is worth noting that several
large clinical studies have recently suggested that the pres-
ence of anti-PF4/H antibodies (measured as a combined
IgG/IgA/IgM immune response) confers a risk of adverse
FIGURE 2. Box plot of interleukin 6 (IL-6) levels according to anti–platelet factor 4/heparin antibody OD levels (0.45 or<0.45) measured at T3 (excluding
14 patients with OD levels 0.45 preoperatively).The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 6 1461
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Poutcomes among certain groups of heparin-treated patients,
even in the absence of clinical HIT. In patients with acute
coronary syndrome, anti-PF4/H antibodies were indepen-
dent predictors of 30-day death and myocardial infarction.18
Two large studies demonstrated that the presence of anti-
PF4/H antibodies before surgical intervention is an indepen-
dent predictor for death, prolonged hospital stay, and organ
dysfunction after adult cardiac surgery.19,20 Interestingly,
none of these studies found evidence of clinical HIT among
these antibody-positive patients, despite the apparent ad-
verse prognostic implications of the antibodies. In our study
we investigated the individual immunoglobulin classes
(IgG, IgA, and IgM) that underlie the anti-PF4/H immune re-
sponse and tested for functionality of the antibodies using
a platelet activation assay (SRA). However, we did not
identify any patients who had the clinical features of HIT
(thrombocytopenia, thrombosis, or both) together with the
expected serologic profile (positive anti-PF4/H IgG-ELISA
result and positive SRA result).
Because the anti-PF4/H immune response is observed
commonly after cardiac surgery and can have adverse prog-
nostic implications, we investigated for a possible relation-
ship between the presence of anti-PF4/H antibodies (a
surrogate marker for the HIT immune response) and perio-
perative inflammation. Cardiac surgery is known to induce
an acute-phase reaction that has been implicated in the path-
ogenesis of several postoperative complications. Different
proinflammatory and anti-inflammatory mediators (cyto-
kines and adhesion molecules) are involved.21 An intense re-
lease of IL-6 has been demonstrated during and after the
operation (with and without CPB),7 and our study confirms
that an activated inflammatory state persists for several days
after the operation. However, no differences in serum IL-6
levels during the perioperative and postoperative periods
were observed between the patients who had anti-PF4/H an-
tibody seroconversion versus those who did not have sero-
conversion. Nevertheless, our data did demonstrate that
patients with positive anti-PF4/H antibody levels at T3 had
higher IL-6 levels during the early postoperative period (Fig-
ure 2), possibly signifying that the intense proinflammatory
response provoked by cardiac surgery facilitates the immune
response against the PF4/heparin complex. Considering that
the amount of inflammatory response provoked by cardiac
operations is higher than any other clinical condition, this
finding might help to clarify the reason why cardiac surgical
patients experience higher anti-PF4/H antibody seroconver-
sion rates compared with other clinical settings with heparin
exposure.2
Increased inflammation itself could be the underlying
cause of adverse prognosis described in the presence of
anti-PF4/H antibodies, despite the absence of clinically evi-
dent HIT.19,20 However, this speculation that arises from the
results of our study needs to be confirmed by specifically de-
signed experimental and clinical studies.1462 The Journal of Thoracic and Cardiovascular SuFinally, our data demonstrate that patients with the HLA
class I CW4 antigen have a higher risk of anti-PF4/H anti-
body seroconversion after heparin exposure during cardiac
operation. Patients with the HLA B35 and B50 antigens
have also a higher risk of seroconversion, but the association
did not remain significant after the Bonferroni correction.
Two previous studies have been published with the aim of
identifying an HLA involvement in HIT immune reactions.
Greinacher and Mueller–Eckhart5 did not find any associa-
tion between HLA class I and class II antigens and immune
HIT, which was confirmed in 47 patients by means of a plate-
let activation assay. Our group, in a prospective evaluation
of 69 patients undergoing CPB surgery, found a significantly
higher incidence (without the Bonferroni correction) of the
HLA class II DRB1*03 allele among 10 patients with anti-
PF4/H antibodies (absorbance values, 0.40 OD units) in
at least one of the collected samples.6 Several factors render
the present study more reliable: stronger statistical evidence
obtained with the Bonferroni correction, strict criteria used
to identify seroconversion, better sampling time to evaluate
postoperative seroconversion (14 days after heparin expo-
sure, the time when anti-PF4/H antibodies usually reach
peak levels, rather than 7 and 21 days after), and more ad-
vanced HLA tissue-typing techniques. We consider the pres-
ent finding interesting because the same alleles have been
identified in association with several (auto)immune disor-
ders, such as rheumatoid arthritis,22 thyroiditis,23 and
AIDS.24 Our experience provides additional evidence that
the HLA-CW4 antigen confers genetic susceptibility in ac-
quiring acute or subacute inflammatory disease, in this
case the anti-PF4/H immune response.
Some limitations of our study should be discussed. Our
results do not rule out a possible influence of platelet-asso-
ciated PF4 levels, nor do they rule out the possibility that
differing quantities of multimolecular PF4/heparin com-
plexes formed on cell surfaces could influence the risk of
seroconversion. Moreover, our sample size is not adequate
to provide information into whether adverse clinical out-
comes are associated with an anti-PF4/H immune response.
Our study also was not designed to evaluate whether
HLA status influences the postoperative inflammatory
response.
In summary, our study provides evidence that both ge-
netic factors (HLA status) and acquired factors (periopera-
tive inflammation, as assessed based on IL-6 levels) might
influence the anti-PF4/H immune response. Because several
pharmacologic, device-related, and technical strategies exist
to attenuate inflammatory response after cardiac surgery, fu-
ture studies should clarify whether a reduced inflammatory
response might attenuate the risk of anti-PF4/H antibodies
seroconversion after cardiac surgery.
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